Key Market Indicators
Slovene antihypertensive medicine sales are set to reach nearly $4.4 million by 2026. In 2021, sales reached $4.5 million, down slightly from the year before. Since 2012, demand for these medicines has grown by an average of 5% each year. Slovenia ranked 20th in 2021, behind Latvia, which recorded sales of $4.5 million. Italy, Spain and Australia ranked second, third and fourth, respectively.
